nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—MPO—Dapsone—leprosy	0.284	0.411	CbGbCtD
Mesalazine—PTGS2—Thalidomide—leprosy	0.123	0.177	CbGbCtD
Mesalazine—PTGS1—Thalidomide—leprosy	0.104	0.15	CbGbCtD
Mesalazine—PTGS2—Dapsone—leprosy	0.0981	0.142	CbGbCtD
Mesalazine—PTGS1—Dapsone—leprosy	0.0828	0.12	CbGbCtD
Mesalazine—Pulmonary eosinophilia—Dapsone—leprosy	0.0075	0.0549	CcSEcCtD
Mesalazine—Lupus-like syndrome—Dapsone—leprosy	0.00581	0.0426	CcSEcCtD
Mesalazine—PPARG—hindlimb—leprosy	0.00466	0.113	CbGeAlD
Mesalazine—Olsalazine—IFNG—leprosy	0.00426	1	CrCbGaD
Mesalazine—PPARG—appendage—leprosy	0.004	0.0972	CbGeAlD
Mesalazine—Nephrotic syndrome—Dapsone—leprosy	0.00283	0.0208	CcSEcCtD
Mesalazine—MPO—blood vessel—leprosy	0.00251	0.061	CbGeAlD
Mesalazine—CHUK—skin of body—leprosy	0.00243	0.0592	CbGeAlD
Mesalazine—Lacrimal structural disorder—Thalidomide—leprosy	0.00239	0.0175	CcSEcCtD
Mesalazine—Lipase increased—Thalidomide—leprosy	0.00239	0.0175	CcSEcCtD
Mesalazine—PTGS2—hindlimb—leprosy	0.00238	0.0579	CbGeAlD
Mesalazine—PPARG—blood vessel—leprosy	0.00222	0.0541	CbGeAlD
Mesalazine—PTGS2—appendage—leprosy	0.00204	0.0497	CbGeAlD
Mesalazine—Skin necrosis—Thalidomide—leprosy	0.00201	0.0147	CcSEcCtD
Mesalazine—Albuminuria—Dapsone—leprosy	0.00184	0.0134	CcSEcCtD
Mesalazine—PTGS2—skin epidermis—leprosy	0.0017	0.0413	CbGeAlD
Mesalazine—IKBKB—skin of body—leprosy	0.00166	0.0402	CbGeAlD
Mesalazine—Erythema nodosum—Thalidomide—leprosy	0.00162	0.0119	CcSEcCtD
Mesalazine—Pericarditis—Thalidomide—leprosy	0.00162	0.0119	CcSEcCtD
Mesalazine—Lacrimal disorder—Thalidomide—leprosy	0.00157	0.0115	CcSEcCtD
Mesalazine—Proteinuria—Dapsone—leprosy	0.00156	0.0114	CcSEcCtD
Mesalazine—Protein urine present—Dapsone—leprosy	0.00154	0.0113	CcSEcCtD
Mesalazine—CHUK—testis—leprosy	0.00153	0.0373	CbGeAlD
Mesalazine—Tongue discolouration—Thalidomide—leprosy	0.00145	0.0106	CcSEcCtD
Mesalazine—Lactic dehydrogenase activity increased—Thalidomide—leprosy	0.00137	0.01	CcSEcCtD
Mesalazine—Skin exfoliation—Dapsone—leprosy	0.00131	0.00957	CcSEcCtD
Mesalazine—IKBKB—tendon—leprosy	0.00126	0.0306	CbGeAlD
Mesalazine—CHUK—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—leprosy	0.00126	0.0099	CbGpPWpGaD
Mesalazine—Foetor hepaticus—Thalidomide—leprosy	0.00124	0.00905	CcSEcCtD
Mesalazine—IKBKB—TNF receptor signaling pathway —CYLD—leprosy	0.00123	0.00974	CbGpPWpGaD
Mesalazine—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00121	0.00883	CcSEcCtD
Mesalazine—CHUK—NOD1/2 Signaling Pathway—RIPK2—leprosy	0.0012	0.00949	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—LTA—leprosy	0.00119	0.00942	CbGpPWpGaD
Mesalazine—PTGS1—blood vessel—leprosy	0.00119	0.0289	CbGeAlD
Mesalazine—Platelet count decreased—Thalidomide—leprosy	0.00118	0.00863	CcSEcCtD
Mesalazine—Enlargement abdomen—Thalidomide—leprosy	0.00117	0.00853	CcSEcCtD
Mesalazine—MPO—skin of body—leprosy	0.00116	0.0282	CbGeAlD
Mesalazine—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CYLD—leprosy	0.00115	0.00911	CbGpPWpGaD
Mesalazine—IKBKB—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—leprosy	0.00114	0.00898	CbGpPWpGaD
Mesalazine—PTGS2—blood vessel—leprosy	0.00114	0.0276	CbGeAlD
Mesalazine—Psoriasis—Thalidomide—leprosy	0.00112	0.00817	CcSEcCtD
Mesalazine—Oral candidiasis—Thalidomide—leprosy	0.0011	0.00808	CcSEcCtD
Mesalazine—Hypomagnesaemia—Thalidomide—leprosy	0.0011	0.00808	CcSEcCtD
Mesalazine—IKBKB—NOD1/2 Signaling Pathway—RIPK2—leprosy	0.00109	0.00861	CbGpPWpGaD
Mesalazine—CHUK—NOD1/2 Signaling Pathway—NOD2—leprosy	0.00109	0.0086	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—LTA—leprosy	0.00108	0.00854	CbGpPWpGaD
Mesalazine—Nail disorder—Thalidomide—leprosy	0.00108	0.00792	CcSEcCtD
Mesalazine—IKBKB—testis—leprosy	0.00104	0.0254	CbGeAlD
Mesalazine—PPARG—skin of body—leprosy	0.00103	0.025	CbGeAlD
Mesalazine—Intestinal obstruction—Thalidomide—leprosy	0.00103	0.00753	CcSEcCtD
Mesalazine—Liver disorder—Thalidomide—leprosy	0.00103	0.00753	CcSEcCtD
Mesalazine—IKBKB—nervous system—leprosy	0.00102	0.0249	CbGeAlD
Mesalazine—Burning sensation—Thalidomide—leprosy	0.00101	0.00739	CcSEcCtD
Mesalazine—Thrombosis—Thalidomide—leprosy	0.000991	0.00725	CcSEcCtD
Mesalazine—Lung disorder—Thalidomide—leprosy	0.000991	0.00725	CcSEcCtD
Mesalazine—Interstitial lung disease—Thalidomide—leprosy	0.000991	0.00725	CcSEcCtD
Mesalazine—IKBKB—NOD1/2 Signaling Pathway—NOD2—leprosy	0.000989	0.0078	CbGpPWpGaD
Mesalazine—Metrorrhagia—Thalidomide—leprosy	0.000982	0.00719	CcSEcCtD
Mesalazine—CHUK—Interleukin-1 signaling—RIPK2—leprosy	0.000981	0.00774	CbGpPWpGaD
Mesalazine—CHUK—Downstream TCR signaling—RIPK2—leprosy	0.000962	0.00759	CbGpPWpGaD
Mesalazine—CHUK—NOD pathway—RIPK2—leprosy	0.000962	0.00759	CbGpPWpGaD
Mesalazine—Albuminuria—Thalidomide—leprosy	0.000939	0.00688	CcSEcCtD
Mesalazine—Cholestasis—Thalidomide—leprosy	0.000924	0.00676	CcSEcCtD
Mesalazine—Pleural effusion—Thalidomide—leprosy	0.000916	0.0067	CcSEcCtD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.000911	0.00719	CbGpPWpGaD
Mesalazine—Amblyopia—Thalidomide—leprosy	0.000908	0.00665	CcSEcCtD
Mesalazine—Hyperaesthesia—Thalidomide—leprosy	0.000894	0.00654	CcSEcCtD
Mesalazine—IKBKB—Interleukin-1 signaling—RIPK2—leprosy	0.00089	0.00702	CbGpPWpGaD
Mesalazine—CHUK—Interleukin-1 signaling—NOD2—leprosy	0.000889	0.00702	CbGpPWpGaD
Mesalazine—Nasopharyngitis—Dapsone—leprosy	0.000889	0.00651	CcSEcCtD
Mesalazine—Rash pustular—Thalidomide—leprosy	0.000879	0.00644	CcSEcCtD
Mesalazine—CHUK—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—CYLD—leprosy	0.000874	0.0069	CbGpPWpGaD
Mesalazine—IKBKB—Downstream TCR signaling—RIPK2—leprosy	0.000872	0.00688	CbGpPWpGaD
Mesalazine—IKBKB—NOD pathway—RIPK2—leprosy	0.000872	0.00688	CbGpPWpGaD
Mesalazine—CHUK—NOD pathway—NOD2—leprosy	0.000872	0.00688	CbGpPWpGaD
Mesalazine—ALOX5—testis—leprosy	0.000865	0.021	CbGeAlD
Mesalazine—Influenza—Dapsone—leprosy	0.00086	0.00629	CcSEcCtD
Mesalazine—MPO—IL23-mediated signaling events—IFNG—leprosy	0.000858	0.00677	CbGpPWpGaD
Mesalazine—ALOX5—nervous system—leprosy	0.000849	0.0206	CbGeAlD
Mesalazine—Pancreatitis—Dapsone—leprosy	0.000843	0.00617	CcSEcCtD
Mesalazine—Blood disorder—Thalidomide—leprosy	0.00084	0.00615	CcSEcCtD
Mesalazine—Acne—Thalidomide—leprosy	0.000834	0.0061	CcSEcCtD
Mesalazine—MPO—IL23-mediated signaling events—CD4—leprosy	0.000829	0.00654	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.000826	0.00652	CbGpPWpGaD
Mesalazine—CHUK—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—RIPK2—leprosy	0.000821	0.00647	CbGpPWpGaD
Mesalazine—IKBKB—Interleukin-1 signaling—NOD2—leprosy	0.000806	0.00636	CbGpPWpGaD
Mesalazine—Vasodilation procedure—Thalidomide—leprosy	0.000798	0.00584	CcSEcCtD
Mesalazine—Jaundice cholestatic—Thalidomide—leprosy	0.000798	0.00584	CcSEcCtD
Mesalazine—Amenorrhoea—Thalidomide—leprosy	0.000798	0.00584	CcSEcCtD
Mesalazine—Vasodilation—Thalidomide—leprosy	0.000798	0.00584	CcSEcCtD
Mesalazine—Proteinuria—Thalidomide—leprosy	0.000798	0.00584	CcSEcCtD
Mesalazine—IKBKB—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—CYLD—leprosy	0.000793	0.00626	CbGpPWpGaD
Mesalazine—IKBKB—NOD pathway—NOD2—leprosy	0.000791	0.00624	CbGpPWpGaD
Mesalazine—Protein urine present—Thalidomide—leprosy	0.000787	0.00576	CcSEcCtD
Mesalazine—Photosensitivity reaction—Dapsone—leprosy	0.000785	0.00574	CcSEcCtD
Mesalazine—PPARG—tendon—leprosy	0.000784	0.0191	CbGeAlD
Mesalazine—Musculoskeletal stiffness—Thalidomide—leprosy	0.000782	0.00572	CcSEcCtD
Mesalazine—Skin discolouration—Thalidomide—leprosy	0.000777	0.00568	CcSEcCtD
Mesalazine—Bone disorder—Thalidomide—leprosy	0.000777	0.00568	CcSEcCtD
Mesalazine—Arthropathy—Thalidomide—leprosy	0.000771	0.00565	CcSEcCtD
Mesalazine—Hypocalcaemia—Thalidomide—leprosy	0.000766	0.00561	CcSEcCtD
Mesalazine—MPO—IL23-mediated signaling events—IL2—leprosy	0.000762	0.00602	CbGpPWpGaD
Mesalazine—Neuropathy peripheral—Dapsone—leprosy	0.000751	0.0055	CcSEcCtD
Mesalazine—Leukocytosis—Thalidomide—leprosy	0.000746	0.00546	CcSEcCtD
Mesalazine—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—RIPK2—leprosy	0.000744	0.00587	CbGpPWpGaD
Mesalazine—CHUK—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—leprosy	0.000744	0.00587	CbGpPWpGaD
Mesalazine—MPO—testis—leprosy	0.000732	0.0178	CbGeAlD
Mesalazine—Sinusitis—Dapsone—leprosy	0.000719	0.00526	CcSEcCtD
Mesalazine—CHUK—TCR signaling—RIPK2—leprosy	0.000719	0.00567	CbGpPWpGaD
Mesalazine—MPO—nervous system—leprosy	0.000718	0.0175	CbGeAlD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	0.000711	0.00561	CbGpPWpGaD
Mesalazine—Neck pain—Thalidomide—leprosy	0.00071	0.0052	CcSEcCtD
Mesalazine—Phosphatase alkaline increased—Thalidomide—leprosy	0.000701	0.00513	CcSEcCtD
Mesalazine—Hepatocellular injury—Thalidomide—leprosy	0.000701	0.00513	CcSEcCtD
Mesalazine—Eructation—Thalidomide—leprosy	0.000689	0.00504	CcSEcCtD
Mesalazine—Pharyngitis—Dapsone—leprosy	0.000683	0.005	CcSEcCtD
Mesalazine—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—leprosy	0.000675	0.00532	CbGpPWpGaD
Mesalazine—Colitis—Thalidomide—leprosy	0.000673	0.00493	CcSEcCtD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	0.00067	0.00529	CbGpPWpGaD
Mesalazine—Candida infection—Thalidomide—leprosy	0.00067	0.0049	CcSEcCtD
Mesalazine—Skin exfoliation—Thalidomide—leprosy	0.00067	0.0049	CcSEcCtD
Mesalazine—MPO—Vitamin B12 Metabolism—IFNG—leprosy	0.000664	0.00524	CbGpPWpGaD
Mesalazine—Blood urea increased—Thalidomide—leprosy	0.000662	0.00485	CcSEcCtD
Mesalazine—Aplastic anaemia—Thalidomide—leprosy	0.000659	0.00482	CcSEcCtD
Mesalazine—Neuropathy—Thalidomide—leprosy	0.000659	0.00482	CcSEcCtD
Mesalazine—IKBKB—TCR signaling—RIPK2—leprosy	0.000652	0.00514	CbGpPWpGaD
Mesalazine—PPARG—testis—leprosy	0.000649	0.0158	CbGeAlD
Mesalazine—Dry eye—Thalidomide—leprosy	0.000648	0.00474	CcSEcCtD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	0.000645	0.00509	CbGpPWpGaD
Mesalazine—Cramps of lower extremities—Thalidomide—leprosy	0.000644	0.00472	CcSEcCtD
Mesalazine—Tinnitus—Dapsone—leprosy	0.000641	0.0047	CcSEcCtD
Mesalazine—PPARG—nervous system—leprosy	0.000637	0.0155	CbGeAlD
Mesalazine—CHUK—p75(NTR)-mediated signaling—RIPK2—leprosy	0.000634	0.005	CbGpPWpGaD
Mesalazine—Hypertonia—Thalidomide—leprosy	0.000615	0.0045	CcSEcCtD
Mesalazine—Erythema—Dapsone—leprosy	0.000599	0.00438	CcSEcCtD
Mesalazine—Lymphadenopathy—Thalidomide—leprosy	0.000597	0.00437	CcSEcCtD
Mesalazine—CHUK—TCR signaling in naïve CD8+ T cells—CD8A—leprosy	0.000594	0.00468	CbGpPWpGaD
Mesalazine—CHUK—Downstream TCR signaling—HLA-DRB1—leprosy	0.000594	0.00468	CbGpPWpGaD
Mesalazine—CHUK—TRAF6 Mediated Induction of proinflammatory cytokines—RIPK2—leprosy	0.000593	0.00468	CbGpPWpGaD
Mesalazine—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.000585	0.00428	CcSEcCtD
Mesalazine—Photosensitivity—Thalidomide—leprosy	0.00058	0.00424	CcSEcCtD
Mesalazine—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.000576	0.00454	CbGpPWpGaD
Mesalazine—IKBKB—p75(NTR)-mediated signaling—RIPK2—leprosy	0.000575	0.00454	CbGpPWpGaD
Mesalazine—Gastroenteritis—Thalidomide—leprosy	0.000574	0.0042	CcSEcCtD
Mesalazine—Deafness—Thalidomide—leprosy	0.000569	0.00417	CcSEcCtD
Mesalazine—Eczema—Thalidomide—leprosy	0.000567	0.00415	CcSEcCtD
Mesalazine—Vision blurred—Dapsone—leprosy	0.000564	0.00413	CcSEcCtD
Mesalazine—Eye pain—Thalidomide—leprosy	0.000564	0.00413	CcSEcCtD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	0.000562	0.00443	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—TNF—leprosy	0.000555	0.00438	CbGpPWpGaD
Mesalazine—Renal failure acute—Thalidomide—leprosy	0.000551	0.00404	CcSEcCtD
Mesalazine—PTGS1—skin of body—leprosy	0.000551	0.0134	CbGeAlD
Mesalazine—Libido decreased—Thalidomide—leprosy	0.000549	0.00402	CcSEcCtD
Mesalazine—Increased appetite—Thalidomide—leprosy	0.000542	0.00397	CcSEcCtD
Mesalazine—MPO—Folate Metabolism—IFNG—leprosy	0.00054	0.00426	CbGpPWpGaD
Mesalazine—IKBKB—TCR signaling in naïve CD8+ T cells—CD8A—leprosy	0.000538	0.00425	CbGpPWpGaD
Mesalazine—IKBKB—Downstream TCR signaling—HLA-DRB1—leprosy	0.000538	0.00425	CbGpPWpGaD
Mesalazine—Vertigo—Dapsone—leprosy	0.000538	0.00394	CcSEcCtD
Mesalazine—IKBKB—TRAF6 Mediated Induction of proinflammatory cytokines—RIPK2—leprosy	0.000538	0.00424	CbGpPWpGaD
Mesalazine—CHUK—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—leprosy	0.000538	0.00424	CbGpPWpGaD
Mesalazine—Atrial fibrillation—Thalidomide—leprosy	0.000537	0.00393	CcSEcCtD
Mesalazine—CHUK—MyD88 cascade initiated on plasma membrane—RIPK2—leprosy	0.000537	0.00423	CbGpPWpGaD
Mesalazine—Dermatitis bullous—Thalidomide—leprosy	0.000533	0.0039	CcSEcCtD
Mesalazine—CHUK—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—RIPK2—leprosy	0.000532	0.0042	CbGpPWpGaD
Mesalazine—PTGS2—skin of body—leprosy	0.000526	0.0128	CbGeAlD
Mesalazine—Arthritis—Thalidomide—leprosy	0.000524	0.00383	CcSEcCtD
Mesalazine—Cough—Dapsone—leprosy	0.000523	0.00383	CcSEcCtD
Mesalazine—CHUK—MyD88 dependent cascade initiated on endosome—RIPK2—leprosy	0.000522	0.00412	CbGpPWpGaD
Mesalazine—Lethargy—Thalidomide—leprosy	0.00052	0.0038	CcSEcCtD
Mesalazine—CHUK—TCR Signaling Pathway—RIPK2—leprosy	0.000513	0.00405	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	0.00051	0.00402	CbGpPWpGaD
Mesalazine—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000509	0.00373	CcSEcCtD
Mesalazine—Osteoarthritis—Thalidomide—leprosy	0.000509	0.00373	CcSEcCtD
Mesalazine—Disturbance in sexual arousal—Thalidomide—leprosy	0.000505	0.0037	CcSEcCtD
Mesalazine—CHUK—Toll Like Receptor 9 (TLR9) Cascade—RIPK2—leprosy	0.000504	0.00398	CbGpPWpGaD
Mesalazine—Migraine—Thalidomide—leprosy	0.000501	0.00367	CcSEcCtD
Mesalazine—Affect lability—Thalidomide—leprosy	0.000501	0.00367	CcSEcCtD
Mesalazine—IKBKB—p75 NTR receptor-mediated signalling—RIPK2—leprosy	0.000501	0.00395	CbGpPWpGaD
Mesalazine—CHUK—MyD88:Mal cascade initiated on plasma membrane—TLR2—leprosy	0.000495	0.00391	CbGpPWpGaD
Mesalazine—CHUK—MyD88:Mal cascade initiated on plasma membrane—RIPK2—leprosy	0.000495	0.00391	CbGpPWpGaD
Mesalazine—PPARG—Transcription factor regulation in adipogenesis—TNF—leprosy	0.000492	0.00388	CbGpPWpGaD
Mesalazine—Face oedema—Thalidomide—leprosy	0.000492	0.0036	CcSEcCtD
Mesalazine—IKBKB—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—leprosy	0.000488	0.00385	CbGpPWpGaD
Mesalazine—IKBKB—MyD88 cascade initiated on plasma membrane—RIPK2—leprosy	0.000487	0.00384	CbGpPWpGaD
Mesalazine—CHUK—MyD88 cascade initiated on plasma membrane—NOD2—leprosy	0.000487	0.00384	CbGpPWpGaD
Mesalazine—Mood swings—Thalidomide—leprosy	0.000482	0.00353	CcSEcCtD
Mesalazine—IKBKB—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—RIPK2—leprosy	0.000482	0.0038	CbGpPWpGaD
Mesalazine—CHUK—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—leprosy	0.000482	0.0038	CbGpPWpGaD
Mesalazine—MPO—Folate Metabolism—IL2—leprosy	0.00048	0.00379	CbGpPWpGaD
Mesalazine—Tachycardia—Dapsone—leprosy	0.000477	0.00349	CcSEcCtD
Mesalazine—Blood creatinine increased—Thalidomide—leprosy	0.000477	0.00349	CcSEcCtD
Mesalazine—CHUK—MyD88-independent cascade—RIPK2—leprosy	0.000475	0.00375	CbGpPWpGaD
Mesalazine—IKBKB—MyD88 dependent cascade initiated on endosome—RIPK2—leprosy	0.000473	0.00374	CbGpPWpGaD
Mesalazine—CHUK—MyD88 dependent cascade initiated on endosome—NOD2—leprosy	0.000473	0.00373	CbGpPWpGaD
Mesalazine—Liver function test abnormal—Thalidomide—leprosy	0.00047	0.00344	CcSEcCtD
Mesalazine—Dry skin—Thalidomide—leprosy	0.000467	0.00342	CcSEcCtD
Mesalazine—Orthostatic hypotension—Thalidomide—leprosy	0.000465	0.0034	CcSEcCtD
Mesalazine—IKBKB—TCR Signaling Pathway—RIPK2—leprosy	0.000465	0.00367	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—TLR2—leprosy	0.000464	0.00366	CbGpPWpGaD
Mesalazine—Breast disorder—Thalidomide—leprosy	0.00046	0.00337	CcSEcCtD
Mesalazine—Cramp muscle—Thalidomide—leprosy	0.000458	0.00336	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Thalidomide—leprosy	0.000458	0.00336	CcSEcCtD
Mesalazine—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—RIPK2—leprosy	0.000457	0.0036	CbGpPWpGaD
Mesalazine—CHUK—Toll Like Receptor 9 (TLR9) Cascade—NOD2—leprosy	0.000457	0.0036	CbGpPWpGaD
Mesalazine—IKBKB—MyD88:Mal cascade initiated on plasma membrane—TLR2—leprosy	0.000449	0.00354	CbGpPWpGaD
Mesalazine—IKBKB—MyD88:Mal cascade initiated on plasma membrane—RIPK2—leprosy	0.000449	0.00354	CbGpPWpGaD
Mesalazine—Alanine aminotransferase increased—Thalidomide—leprosy	0.000449	0.00329	CcSEcCtD
Mesalazine—CHUK—MyD88:Mal cascade initiated on plasma membrane—NOD2—leprosy	0.000449	0.00354	CbGpPWpGaD
Mesalazine—CHUK—EBV LMP1 signaling—TNF—leprosy	0.000446	0.00352	CbGpPWpGaD
Mesalazine—CHUK—Canonical NF-kappaB pathway—TNF—leprosy	0.000446	0.00352	CbGpPWpGaD
Mesalazine—CHUK—TCR signaling—HLA-DRB1—leprosy	0.000444	0.0035	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—RIPK2—leprosy	0.000443	0.0035	CbGpPWpGaD
Mesalazine—Abdominal distension—Thalidomide—leprosy	0.000443	0.00324	CcSEcCtD
Mesalazine—Insomnia—Dapsone—leprosy	0.000442	0.00324	CcSEcCtD
Mesalazine—IKBKB—MyD88 cascade initiated on plasma membrane—NOD2—leprosy	0.000441	0.00348	CbGpPWpGaD
Mesalazine—Dysphagia—Thalidomide—leprosy	0.00044	0.00322	CcSEcCtD
Mesalazine—Influenza—Thalidomide—leprosy	0.00044	0.00322	CcSEcCtD
Mesalazine—IKBKB—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—leprosy	0.000437	0.00345	CbGpPWpGaD
Mesalazine—Eosinophilia—Thalidomide—leprosy	0.000436	0.00319	CcSEcCtD
Mesalazine—Bronchospasm—Thalidomide—leprosy	0.000433	0.00317	CcSEcCtD
Mesalazine—Pancreatitis—Thalidomide—leprosy	0.000431	0.00316	CcSEcCtD
Mesalazine—IKBKB—MyD88-independent cascade—RIPK2—leprosy	0.000431	0.0034	CbGpPWpGaD
Mesalazine—CHUK—MyD88-independent cascade—NOD2—leprosy	0.000431	0.0034	CbGpPWpGaD
Mesalazine—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—leprosy	0.00043	0.00339	CbGpPWpGaD
Mesalazine—MPO—C-MYB transcription factor network—CD4—leprosy	0.00043	0.00339	CbGpPWpGaD
Mesalazine—MPO—Vitamin B12 Metabolism—TNF—leprosy	0.00043	0.00339	CbGpPWpGaD
Mesalazine—IKBKB—MyD88 dependent cascade initiated on endosome—NOD2—leprosy	0.000429	0.00339	CbGpPWpGaD
Mesalazine—MPO—Selenium Micronutrient Network—IFNG—leprosy	0.000429	0.00338	CbGpPWpGaD
Mesalazine—Angina pectoris—Thalidomide—leprosy	0.000429	0.00314	CcSEcCtD
Mesalazine—CHUK—Activated TLR4 signalling—RIPK2—leprosy	0.000427	0.00337	CbGpPWpGaD
Mesalazine—CHUK—Activated TLR4 signalling—TLR2—leprosy	0.000427	0.00337	CbGpPWpGaD
Mesalazine—Bronchitis—Thalidomide—leprosy	0.000423	0.0031	CcSEcCtD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—TLR2—leprosy	0.000421	0.00332	CbGpPWpGaD
Mesalazine—PTGS1—tendon—leprosy	0.000419	0.0102	CbGeAlD
Mesalazine—CHUK—Downstream TCR signaling—CD4—leprosy	0.000419	0.0033	CbGpPWpGaD
Mesalazine—IKBKB—Type II diabetes mellitus—TNF—leprosy	0.000419	0.0033	CbGpPWpGaD
Mesalazine—Pancytopenia—Thalidomide—leprosy	0.000418	0.00306	CcSEcCtD
Mesalazine—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—NOD2—leprosy	0.000414	0.00327	CbGpPWpGaD
Mesalazine—Neutropenia—Thalidomide—leprosy	0.000411	0.00301	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Thalidomide—leprosy	0.000409	0.00299	CcSEcCtD
Mesalazine—IKBKB—MyD88:Mal cascade initiated on plasma membrane—NOD2—leprosy	0.000407	0.00321	CbGpPWpGaD
Mesalazine—Pollakiuria—Thalidomide—leprosy	0.000406	0.00298	CcSEcCtD
Mesalazine—CHUK—TCR signaling in naïve CD4+ T cells—HLA-DRB1—leprosy	0.000406	0.0032	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—IFNG—leprosy	0.000405	0.00319	CbGpPWpGaD
Mesalazine—IKBKB—Canonical NF-kappaB pathway—TNF—leprosy	0.000404	0.00319	CbGpPWpGaD
Mesalazine—IKBKB—EBV LMP1 signaling—TNF—leprosy	0.000404	0.00319	CbGpPWpGaD
Mesalazine—IKBKB—TCR signaling—HLA-DRB1—leprosy	0.000402	0.00317	CbGpPWpGaD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—RIPK2—leprosy	0.000402	0.00317	CbGpPWpGaD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—TLR2—leprosy	0.000402	0.00317	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—RIPK2—leprosy	0.000402	0.00317	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—NOD2—leprosy	0.000402	0.00317	CbGpPWpGaD
Mesalazine—Photosensitivity reaction—Thalidomide—leprosy	0.000402	0.00294	CcSEcCtD
Mesalazine—PTGS2—tendon—leprosy	0.000401	0.00974	CbGeAlD
Mesalazine—Weight increased—Thalidomide—leprosy	0.0004	0.00293	CcSEcCtD
Mesalazine—Gastrointestinal pain—Dapsone—leprosy	0.0004	0.00293	CcSEcCtD
Mesalazine—Weight decreased—Thalidomide—leprosy	0.000398	0.00291	CcSEcCtD
Mesalazine—Pneumonia—Thalidomide—leprosy	0.000395	0.00289	CcSEcCtD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	0.000394	0.00311	CbGpPWpGaD
Mesalazine—Infestation NOS—Thalidomide—leprosy	0.000392	0.00287	CcSEcCtD
Mesalazine—Infestation—Thalidomide—leprosy	0.000392	0.00287	CcSEcCtD
Mesalazine—Depression—Thalidomide—leprosy	0.000391	0.00286	CcSEcCtD
Mesalazine—IKBKB—MyD88-independent cascade—NOD2—leprosy	0.000391	0.00308	CbGpPWpGaD
Mesalazine—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000389	0.00285	CcSEcCtD
Mesalazine—CHUK—TCR Signaling Pathway—CD8A—leprosy	0.000389	0.00307	CbGpPWpGaD
Mesalazine—IKBKB—Activated TLR4 signalling—TLR2—leprosy	0.000388	0.00306	CbGpPWpGaD
Mesalazine—IKBKB—Activated TLR4 signalling—RIPK2—leprosy	0.000388	0.00306	CbGpPWpGaD
Mesalazine—CHUK—Activated TLR4 signalling—NOD2—leprosy	0.000388	0.00306	CbGpPWpGaD
Mesalazine—PTGS1—Overview of nanoparticle effects—TNF—leprosy	0.000387	0.00306	CbGpPWpGaD
Mesalazine—Abdominal pain—Dapsone—leprosy	0.000386	0.00283	CcSEcCtD
Mesalazine—Body temperature increased—Dapsone—leprosy	0.000386	0.00283	CcSEcCtD
Mesalazine—Renal failure—Thalidomide—leprosy	0.000386	0.00282	CcSEcCtD
Mesalazine—Neuropathy peripheral—Thalidomide—leprosy	0.000385	0.00282	CcSEcCtD
Mesalazine—Stomatitis—Thalidomide—leprosy	0.000382	0.0028	CcSEcCtD
Mesalazine—Conjunctivitis—Thalidomide—leprosy	0.000381	0.00279	CcSEcCtD
Mesalazine—IKBKB—Downstream TCR signaling—CD4—leprosy	0.00038	0.003	CbGpPWpGaD
Mesalazine—Sweating—Thalidomide—leprosy	0.000376	0.00275	CcSEcCtD
Mesalazine—Haematuria—Thalidomide—leprosy	0.000374	0.00274	CcSEcCtD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	0.000373	0.00294	CbGpPWpGaD
Mesalazine—Epistaxis—Thalidomide—leprosy	0.00037	0.00271	CcSEcCtD
Mesalazine—Sinusitis—Thalidomide—leprosy	0.000368	0.00269	CcSEcCtD
Mesalazine—IKBKB—TCR signaling in naïve CD4+ T cells—HLA-DRB1—leprosy	0.000368	0.0029	CbGpPWpGaD
Mesalazine—Agranulocytosis—Thalidomide—leprosy	0.000366	0.00268	CcSEcCtD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—TLR2—leprosy	0.000365	0.00288	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—RIPK2—leprosy	0.000365	0.00288	CbGpPWpGaD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—NOD2—leprosy	0.000364	0.00288	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—NOD2—leprosy	0.000364	0.00287	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	0.000362	0.00286	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—TLR2—leprosy	0.000358	0.00282	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—RIPK2—leprosy	0.000358	0.00282	CbGpPWpGaD
Mesalazine—Rhinitis—Thalidomide—leprosy	0.000353	0.00258	CcSEcCtD
Mesalazine—IKBKB—TCR Signaling Pathway—CD8A—leprosy	0.000352	0.00278	CbGpPWpGaD
Mesalazine—Hepatitis—Thalidomide—leprosy	0.000352	0.00258	CcSEcCtD
Mesalazine—IKBKB—Activated TLR4 signalling—NOD2—leprosy	0.000351	0.00277	CbGpPWpGaD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	0.00035	0.00276	CbGpPWpGaD
Mesalazine—Pharyngitis—Thalidomide—leprosy	0.00035	0.00256	CcSEcCtD
Mesalazine—MPO—Folate Metabolism—TNF—leprosy	0.00035	0.00276	CbGpPWpGaD
Mesalazine—Urinary tract disorder—Thalidomide—leprosy	0.000348	0.00255	CcSEcCtD
Mesalazine—PTGS1—testis—leprosy	0.000347	0.00844	CbGeAlD
Mesalazine—Oedema peripheral—Thalidomide—leprosy	0.000347	0.00254	CcSEcCtD
Mesalazine—Urethral disorder—Thalidomide—leprosy	0.000345	0.00253	CcSEcCtD
Mesalazine—PTGS1—nervous system—leprosy	0.000341	0.00828	CbGeAlD
Mesalazine—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.000339	0.00267	CbGpPWpGaD
Mesalazine—CHUK—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—leprosy	0.000334	0.00263	CbGpPWpGaD
Mesalazine—Erythema multiforme—Thalidomide—leprosy	0.000333	0.00244	CcSEcCtD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—NOD2—leprosy	0.00033	0.00261	CbGpPWpGaD
Mesalazine—Eye disorder—Thalidomide—leprosy	0.000329	0.00241	CcSEcCtD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	0.000328	0.00259	CbGpPWpGaD
Mesalazine—Tinnitus—Thalidomide—leprosy	0.000328	0.0024	CcSEcCtD
Mesalazine—Cardiac disorder—Thalidomide—leprosy	0.000327	0.00239	CcSEcCtD
Mesalazine—PTGS2—nervous system—leprosy	0.000326	0.00792	CbGeAlD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—RIPK2—leprosy	0.000325	0.00256	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—TLR2—leprosy	0.000325	0.00256	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—NOD2—leprosy	0.000325	0.00256	CbGpPWpGaD
Mesalazine—Angiopathy—Thalidomide—leprosy	0.00032	0.00234	CcSEcCtD
Mesalazine—Immune system disorder—Thalidomide—leprosy	0.000318	0.00233	CcSEcCtD
Mesalazine—Mediastinal disorder—Thalidomide—leprosy	0.000317	0.00232	CcSEcCtD
Mesalazine—Chills—Thalidomide—leprosy	0.000316	0.00231	CcSEcCtD
Mesalazine—CHUK—TCR signaling—CD4—leprosy	0.000313	0.00247	CbGpPWpGaD
Mesalazine—Alopecia—Thalidomide—leprosy	0.000311	0.00228	CcSEcCtD
Mesalazine—Vomiting—Dapsone—leprosy	0.000311	0.00227	CcSEcCtD
Mesalazine—Mental disorder—Thalidomide—leprosy	0.000309	0.00226	CcSEcCtD
Mesalazine—PTGS2—Overview of nanoparticle effects—TNF—leprosy	0.000307	0.00243	CbGpPWpGaD
Mesalazine—Headache—Dapsone—leprosy	0.000306	0.00224	CcSEcCtD
Mesalazine—Flatulence—Thalidomide—leprosy	0.000302	0.00221	CcSEcCtD
Mesalazine—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.000301	0.00237	CbGpPWpGaD
Mesalazine—Tension—Thalidomide—leprosy	0.000301	0.0022	CcSEcCtD
Mesalazine—Dysgeusia—Thalidomide—leprosy	0.0003	0.0022	CcSEcCtD
Mesalazine—Nervousness—Thalidomide—leprosy	0.000298	0.00218	CcSEcCtD
Mesalazine—Back pain—Thalidomide—leprosy	0.000297	0.00217	CcSEcCtD
Mesalazine—Muscle spasms—Thalidomide—leprosy	0.000295	0.00216	CcSEcCtD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—NOD2—leprosy	0.000294	0.00232	CbGpPWpGaD
Mesalazine—Nausea—Dapsone—leprosy	0.00029	0.00213	CcSEcCtD
Mesalazine—Vision blurred—Thalidomide—leprosy	0.000289	0.00212	CcSEcCtD
Mesalazine—Tremor—Thalidomide—leprosy	0.000287	0.0021	CcSEcCtD
Mesalazine—CHUK—TCR signaling in naïve CD4+ T cells—CD4—leprosy	0.000286	0.00226	CbGpPWpGaD
Mesalazine—Ill-defined disorder—Thalidomide—leprosy	0.000284	0.00208	CcSEcCtD
Mesalazine—IKBKB—TCR signaling—CD4—leprosy	0.000284	0.00224	CbGpPWpGaD
Mesalazine—Anaemia—Thalidomide—leprosy	0.000283	0.00207	CcSEcCtD
Mesalazine—Angioedema—Thalidomide—leprosy	0.00028	0.00205	CcSEcCtD
Mesalazine—MPO—Selenium Micronutrient Network—TNF—leprosy	0.000278	0.00219	CbGpPWpGaD
Mesalazine—Malaise—Thalidomide—leprosy	0.000276	0.00202	CcSEcCtD
Mesalazine—Vertigo—Thalidomide—leprosy	0.000275	0.00202	CcSEcCtD
Mesalazine—CHUK—TWEAK Signaling Pathway—TNF—leprosy	0.000275	0.00217	CbGpPWpGaD
Mesalazine—Syncope—Thalidomide—leprosy	0.000275	0.00201	CcSEcCtD
Mesalazine—Leukopenia—Thalidomide—leprosy	0.000274	0.00201	CcSEcCtD
Mesalazine—Palpitations—Thalidomide—leprosy	0.000271	0.00198	CcSEcCtD
Mesalazine—Loss of consciousness—Thalidomide—leprosy	0.000269	0.00197	CcSEcCtD
Mesalazine—Cough—Thalidomide—leprosy	0.000268	0.00196	CcSEcCtD
Mesalazine—Hypertension—Thalidomide—leprosy	0.000265	0.00194	CcSEcCtD
Mesalazine—ALOX5—Selenium Micronutrient Network—TNF—leprosy	0.000262	0.00207	CbGpPWpGaD
Mesalazine—Arthralgia—Thalidomide—leprosy	0.000261	0.00191	CcSEcCtD
Mesalazine—Chest pain—Thalidomide—leprosy	0.000261	0.00191	CcSEcCtD
Mesalazine—Myalgia—Thalidomide—leprosy	0.000261	0.00191	CcSEcCtD
Mesalazine—Anxiety—Thalidomide—leprosy	0.00026	0.0019	CcSEcCtD
Mesalazine—IKBKB—TCR signaling in naïve CD4+ T cells—CD4—leprosy	0.000259	0.00205	CbGpPWpGaD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000259	0.0019	CcSEcCtD
Mesalazine—Discomfort—Thalidomide—leprosy	0.000258	0.00189	CcSEcCtD
Mesalazine—CHUK—TNF receptor signaling pathway —TNF—leprosy	0.000256	0.00202	CbGpPWpGaD
Mesalazine—Dry mouth—Thalidomide—leprosy	0.000255	0.00187	CcSEcCtD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—leprosy	0.000255	0.00201	CbGpPWpGaD
Mesalazine—Confusional state—Thalidomide—leprosy	0.000252	0.00185	CcSEcCtD
Mesalazine—Oedema—Thalidomide—leprosy	0.00025	0.00183	CcSEcCtD
Mesalazine—IKBKB—TWEAK Signaling Pathway—TNF—leprosy	0.00025	0.00197	CbGpPWpGaD
Mesalazine—Infection—Thalidomide—leprosy	0.000249	0.00182	CcSEcCtD
Mesalazine—Shock—Thalidomide—leprosy	0.000246	0.0018	CcSEcCtD
Mesalazine—Nervous system disorder—Thalidomide—leprosy	0.000245	0.0018	CcSEcCtD
Mesalazine—Thrombocytopenia—Thalidomide—leprosy	0.000245	0.00179	CcSEcCtD
Mesalazine—Tachycardia—Thalidomide—leprosy	0.000244	0.00179	CcSEcCtD
Mesalazine—Skin disorder—Thalidomide—leprosy	0.000243	0.00178	CcSEcCtD
Mesalazine—Hyperhidrosis—Thalidomide—leprosy	0.000242	0.00177	CcSEcCtD
Mesalazine—Anorexia—Thalidomide—leprosy	0.000239	0.00175	CcSEcCtD
Mesalazine—Hypotension—Thalidomide—leprosy	0.000234	0.00171	CcSEcCtD
Mesalazine—IKBKB—TNF receptor signaling pathway —TNF—leprosy	0.000232	0.00183	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Thalidomide—leprosy	0.000228	0.00167	CcSEcCtD
Mesalazine—Insomnia—Thalidomide—leprosy	0.000226	0.00166	CcSEcCtD
Mesalazine—Paraesthesia—Thalidomide—leprosy	0.000225	0.00164	CcSEcCtD
Mesalazine—CHUK—TCR Signaling Pathway—CD4—leprosy	0.000223	0.00176	CbGpPWpGaD
Mesalazine—Dyspnoea—Thalidomide—leprosy	0.000223	0.00163	CcSEcCtD
Mesalazine—Somnolence—Thalidomide—leprosy	0.000222	0.00163	CcSEcCtD
Mesalazine—CHUK—Cardiac Hypertrophic Response—TNF—leprosy	0.000222	0.00175	CbGpPWpGaD
Mesalazine—Dyspepsia—Thalidomide—leprosy	0.00022	0.00161	CcSEcCtD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	0.000219	0.00173	CbGpPWpGaD
Mesalazine—Decreased appetite—Thalidomide—leprosy	0.000218	0.00159	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Thalidomide—leprosy	0.000216	0.00158	CcSEcCtD
Mesalazine—Fatigue—Thalidomide—leprosy	0.000216	0.00158	CcSEcCtD
Mesalazine—Pain—Thalidomide—leprosy	0.000214	0.00157	CcSEcCtD
Mesalazine—Constipation—Thalidomide—leprosy	0.000214	0.00157	CcSEcCtD
Mesalazine—CHUK—Cytokine Signaling in Immune system—RIPK2—leprosy	0.000207	0.00163	CbGpPWpGaD
Mesalazine—Feeling abnormal—Thalidomide—leprosy	0.000206	0.00151	CcSEcCtD
Mesalazine—Gastrointestinal pain—Thalidomide—leprosy	0.000205	0.0015	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—RIPK2—leprosy	0.000203	0.0016	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—CD4—leprosy	0.000202	0.0016	CbGpPWpGaD
Mesalazine—IKBKB—Cardiac Hypertrophic Response—TNF—leprosy	0.000201	0.00159	CbGpPWpGaD
Mesalazine—Urticaria—Thalidomide—leprosy	0.000199	0.00146	CcSEcCtD
Mesalazine—Abdominal pain—Thalidomide—leprosy	0.000198	0.00145	CcSEcCtD
Mesalazine—Body temperature increased—Thalidomide—leprosy	0.000198	0.00145	CcSEcCtD
Mesalazine—PPARG—Signaling events mediated by HDAC Class I—TNF—leprosy	0.000195	0.00154	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	0.000195	0.00154	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—RIPK2—leprosy	0.000188	0.00148	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—NOD2—leprosy	0.000188	0.00148	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—RIPK2—leprosy	0.000184	0.00145	CbGpPWpGaD
Mesalazine—Hypersensitivity—Thalidomide—leprosy	0.000184	0.00135	CcSEcCtD
Mesalazine—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—leprosy	0.000181	0.00142	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CYLD—leprosy	0.00018	0.00142	CbGpPWpGaD
Mesalazine—Asthenia—Thalidomide—leprosy	0.00018	0.00131	CcSEcCtD
Mesalazine—CHUK—Signaling by Interleukins—IL2—leprosy	0.000177	0.0014	CbGpPWpGaD
Mesalazine—Pruritus—Thalidomide—leprosy	0.000177	0.0013	CcSEcCtD
Mesalazine—PTGS1—Selenium Micronutrient Network—IFNG—leprosy	0.000176	0.00139	CbGpPWpGaD
Mesalazine—Diarrhoea—Thalidomide—leprosy	0.000171	0.00125	CcSEcCtD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NOD2—leprosy	0.00017	0.00134	CbGpPWpGaD
Mesalazine—Dizziness—Thalidomide—leprosy	0.000165	0.00121	CcSEcCtD
Mesalazine—ALOX5—Metabolism—SDHD—leprosy	0.000164	0.00129	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CYLD—leprosy	0.000163	0.00129	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—IL2—leprosy	0.000161	0.00127	CbGpPWpGaD
Mesalazine—Vomiting—Thalidomide—leprosy	0.000159	0.00116	CcSEcCtD
Mesalazine—CHUK—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000158	0.00125	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—TNF—leprosy	0.000158	0.00125	CbGpPWpGaD
Mesalazine—Rash—Thalidomide—leprosy	0.000158	0.00115	CcSEcCtD
Mesalazine—Dermatitis—Thalidomide—leprosy	0.000158	0.00115	CcSEcCtD
Mesalazine—Headache—Thalidomide—leprosy	0.000157	0.00115	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—PARK2—leprosy	0.000153	0.00121	CbGpPWpGaD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—TNF—leprosy	0.000152	0.0012	CbGpPWpGaD
Mesalazine—Nausea—Thalidomide—leprosy	0.000149	0.00109	CcSEcCtD
Mesalazine—CHUK—TNF alpha Signaling Pathway—TNF—leprosy	0.000147	0.00116	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TNF—leprosy	0.000143	0.00113	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000143	0.00113	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—leprosy	0.000142	0.00112	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—CD4—leprosy	0.00014	0.0011	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—IFNG—leprosy	0.000139	0.0011	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PARK2—leprosy	0.000139	0.00109	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—TNF—leprosy	0.000135	0.00107	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—TNF—leprosy	0.000133	0.00105	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	0.000128	0.00101	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—TNF—leprosy	0.000123	0.000968	CbGpPWpGaD
Mesalazine—PPARG—Adipogenesis—TNF—leprosy	0.000119	0.000937	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—RIPK2—leprosy	0.000116	0.000915	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—TLR2—leprosy	0.000116	0.000915	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	0.000116	0.000913	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—TNF—leprosy	0.000114	0.000897	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—RIPK2—leprosy	0.000111	0.000879	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IFNG—leprosy	0.00011	0.00087	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TNF—leprosy	0.000106	0.000834	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—RIPK2—leprosy	0.000105	0.00083	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—TLR2—leprosy	0.000105	0.00083	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NOD2—leprosy	0.000105	0.00083	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CYLD—leprosy	0.000105	0.000827	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—SDHD—leprosy	0.000102	0.000801	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—RIPK2—leprosy	0.000101	0.000797	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL2—leprosy	9.79e-05	0.000773	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TNF—leprosy	9.58e-05	0.000756	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NOD2—leprosy	9.53e-05	0.000752	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CYLD—leprosy	9.51e-05	0.00075	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IFNG—leprosy	9.32e-05	0.000735	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PARK2—leprosy	9.27e-05	0.000731	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—TNF—leprosy	9.02e-05	0.000712	CbGpPWpGaD
Mesalazine—CHUK—Disease—SLC11A1—leprosy	8.56e-05	0.000675	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD40LG—leprosy	8.54e-05	0.000673	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IFNG—leprosy	8.45e-05	0.000667	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD8A—leprosy	8.44e-05	0.000666	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PARK2—leprosy	8.4e-05	0.000663	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL2—leprosy	8.28e-05	0.000654	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TNF—leprosy	8.23e-05	0.000649	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TNF—leprosy	8.19e-05	0.000646	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD40LG—leprosy	7.74e-05	0.000611	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD8A—leprosy	7.65e-05	0.000604	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL2—leprosy	7.51e-05	0.000593	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TNF—leprosy	7.13e-05	0.000563	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SDHD—leprosy	7.11e-05	0.000561	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HLA-DRB1—leprosy	6.87e-05	0.000542	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TLR2—leprosy	6.76e-05	0.000533	CbGpPWpGaD
Mesalazine—CHUK—Immune System—RIPK2—leprosy	6.76e-05	0.000533	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HLA-DRB1—leprosy	6.23e-05	0.000492	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TLR2—leprosy	6.13e-05	0.000483	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RIPK2—leprosy	6.13e-05	0.000483	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NOD2—leprosy	6.12e-05	0.000483	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SDHD—leprosy	5.65e-05	0.000446	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NOD2—leprosy	5.55e-05	0.000438	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD40LG—leprosy	5.18e-05	0.000408	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD8A—leprosy	5.12e-05	0.000404	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SLC11A1—leprosy	5.07e-05	0.0004	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CD4—leprosy	5.05e-05	0.000398	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	4.85e-05	0.000383	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD4—leprosy	4.85e-05	0.000382	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD40LG—leprosy	4.69e-05	0.00037	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD8A—leprosy	4.64e-05	0.000366	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CD4—leprosy	4.58e-05	0.000361	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD4—leprosy	4.4e-05	0.000347	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RIPK2—leprosy	4.37e-05	0.000345	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-DRB1—leprosy	4.17e-05	0.000329	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—leprosy	4.08e-05	0.000322	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RIPK2—leprosy	3.96e-05	0.000312	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-DRB1—leprosy	3.78e-05	0.000298	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNG—leprosy	3.04e-05	0.00024	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD4—leprosy	2.94e-05	0.000232	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNG—leprosy	2.76e-05	0.000218	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD4—leprosy	2.71e-05	0.000214	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—leprosy	2.71e-05	0.000213	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD4—leprosy	2.67e-05	0.00021	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—leprosy	2.45e-05	0.000194	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—leprosy	1.75e-05	0.000138	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD4—leprosy	1.61e-05	0.000127	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—leprosy	1.59e-05	0.000125	CbGpPWpGaD
